Navigation Links
NanoPass Technologies Ltd. and Elcam Medical Enter Into a Strategic Partnership
Date:9/14/2010

NanoPass Technologies Ltd. and Elcam Medical Enter Into a... -- REHOVOT and KIBBUTZ BAR'AM, Israel, September 14, 2010 /PRNewswire/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Nanotechnology, Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Contracts, Joint Ventures, Clinical Trials & Medical Discoveries Click to view news release full screen  

NanoPass Technologies Ltd. and Elcam Medical Enter Into a Strategic Partnership

 

REHOVOT and KIBBUTZ BAR'AM, Israel, September 14, 2010 /PRNewswire/ -- NanoPass Technologies Ltd. ("NanoPass"), a privately held company that develops novel microneedle solutions for painless delivery of drugs and vaccines, announced today that it has recently secured a strategic investment and manufacturing agreement with a leading medical device manufacturer, Elcam Medical ("Elcam"). Existing investors including Ofer Hi Tech and D Partners, also participated in the round.

As part of the investment, Mr. Ehud Raivitz, Elcam's CEO, and Mr. Ilan Neugarten of D Partners, will join NanoPass's Board of Directors. Ehud Raivitz remarked, "We are happy to enter into this partnership with NanoPass. I have been impressed by their innovative technology, positive clinical data and achievements. I look forward to leveraging Elcam's capabilities in production and engineering for the mutual benefit of both companies. The collaboration with NanoPass will enable Elcam to provide its customers with access to the most advanced intradermal delivery technology that can address their needs in various applications."

Dr. Yotam Levin, Chief Executive Officer of NanoPass, commented, "We are excited to enter into this strategic partnership with Elcam, a long time supplier of disposable medical products for the medical and pharma industries. We see a significant synergy between our companies. Along with the regulatory approvals we have recently obtained from the FDA and other regulatory bodies, securing a reliable and highly experienced manufacturer is a key component towards full commercialization of our products. The investment will allow NanoPass to develop additional pharmaceutical clients and prepare for market launch."

About NanoPass Technologies Ltd.

NanoPass Technologies was founded by Dr. Shuki Yeshurun under the auspices of the Naiot Technological Incubator. The company is backed by prominent Israeli and US investors including Ofer Hi Tech, D Partners, WFD Ventures, and more recently, Elcam Medical.

About NanoPass's MicronJet Device

MicronJet is a microneedle-based device for ID delivery of vaccines and drugs. The device allows for consistent, reliable, and simple delivery of the drugs directly into the skin. MicronJet has proven efficacy and safety in multiple applications including seasonal flu vaccines, insulin and lidocaine. MicronJet is approved for marketing in various leading territories.

NanoPass has recently concluded the world's first intradermal h1n1 pandemic flu vaccine study, demonstrating equivalent immunogenicity to intramuscular delivery using 20% of the dose. In other clinical trials conducted by NanoPass and third parties, it has been shown that injecting a seasonal influenza vaccine directly into the skin allows for the reduction of the dose required for the same immune response ("dose sparing"). Further, using an equivalent dose may actually increase a vaccine's immunogenicity.

About Elcam Medical

Elcam Medical (Bar-Am, Israel) is a leading worldwide OEM supplier, servicing the medical industry, specializing in the areas of Fluid Management, Vital Signs Monitoring and Drug Delivery.

Contact: Yotam Levin +972-8-9462905 +972-523-392727 yotam@nanopass.com
'/>"/>

SOURCE NanoPass Technologies LTD.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Energy technologies not enough to sufficiently reduce carbon emissions, NYUs Hoffert concludes
2. BioSpecifics Technologies Corp. to Present at Rodman & Renshaw 12th Annual Healthcare Conference
3. Reportlinker Adds Proteomics - Technologies, Markets and Companies
4. Reportlinker Adds Nanobiotechnologies- Applications, Markets and Companies
5. Statement From Sicel Technologies, Inc.
6. Medisafe 1 Technologies Announces 1-5 Stock Dividend
7. Reportlinker Adds Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies
8. TriLink BioTechnologies to Sponsor Take Me Out to the Ballgame, a SAY San Diego Event Benefiting San Diego Families in Need
9. Life Technologies and SG Biofuels Complete Sequence of Jatropha Genome
10. Novel Stem Cell Therapy From Cellonis Biotechnologies Can Help Children With Diabetes Get Back Their Normal Lives
11. Looking to leap forward on laser and photodetector technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , June 27, 2016  Global demand for ... percent through 2020 to $7.2 billion.  This market ... beverages, cleaning products, biofuel production, animal feed, and ... diagnostics, and biocatalysts). Food and beverages will remain ... by increasing consumption of products containing enzymes in ...
(Date:6/27/2016)... ... June 27, 2016 , ... Newly created 4Sight ... solutions to the healthcare market. The company's primary focus is on new product ... marketing strategies that are necessary to help companies efficiently bring their products to ...
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
Breaking Biology Technology:
(Date:6/21/2016)... 2016 NuData Security announced today that Randy ... principal product architect and that Jon Cunningham ... development. Both will report directly to Christopher ... reflect NuData,s strategic growth in its product and ... demand and customer focus values. ...
(Date:6/15/2016)... June 15, 2016 Transparency ... titled "Gesture Recognition Market by Application Market - Global Industry Analysis ... 2024". According to the report, the  global gesture recognition ... 2015 and is estimated to grow at a ... by 2024.  Increasing application of gesture ...
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. ... a business relationship that includes integrating Syngrafii,s patented ... branch project. This collaboration will result in greater ... the credit union, while maintaining existing document workflow ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
Breaking Biology News(10 mins):